» Articles » PMID: 31376301

Sequestosome-1 (p62) Expression Reveals Chaperone-assisted Selective Autophagy in Immune-mediated Necrotizing Myopathies

Abstract

Diffuse myofiber necrosis in the context of inflammatory myopathy is the hallmark of immune-mediated necrotizing myopathy (IMNM). We have previously shown that skeletal muscle fibers of IMNM patients may display nonrimmed vacuoles and sarcoplasmic irregularities. The dysfunctional chaperone activity has been linked to the defective assembly of skeletal muscle proteins and their degradation via lysosomes, autophagy and the proteasomal machinery. This study was undertaken to highlight a chaperone-assisted selective autophagy (CASA) pathway, functionally involved in protein homeostasis, cell stress and the immune response in skeletal muscle of IMNM patients. Skeletal muscle biopsies from 54 IMNM patients were analyzed by immunostaining, as well as by qPCR. Eight biopsies of sIBM patients served as pathological controls, and eight biopsies of nondisease control subjects were included. Alteration of autophagy was detectable in all IMNM biopsy samples highlighted via a diffuse sarcoplasmic staining pattern by p62 and LC3 independent of vacuoles. This pattern was at variance with the coarse focal staining pattern mostly confined to rimmed vacuoles in sIBM. Colocalization of p62 with the chaperone proteins HSP70 and αB-crystalline points to the specific targeting of misfolded proteins to the CASA machinery. Bcl2-associated athanogene 3 (BAG3) positivity of these fibers emphasizes the selectivity of autophagy processes and these fibers also express MHC class I sarcolemma. Expression of genes involved in autophagy and endoplasmic reticulum (ER) stress pathways studied here is significantly upregulated in IMNM. We highlight that vacuoles without sarcolemmal features may arise in IMNM muscle biopsies, and they must not be confounded with sIBM-specific vacuoles. Further, we show the activation of selective autophagy and emphasize the role of chaperones in this context. CASA occurs in IMNM muscle, and specific molecular pathways of autophagy differ from the ones in sIBM, with p62 as a unique identifier of this process.

Citing Articles

Anti-mitochondrial M2 antibody-positive myositis may be an independent subtype of autoimmune myositis.

Nishimori Y, Tanboon J, Oyama M, Motegi H, Tomo Y, Oba M J Neurol. 2025; 272(3):206.

PMID: 39954092 DOI: 10.1007/s00415-025-12945-0.


A window into intracellular events in myositis through subcellular proteomics.

Peterson J, Leclair V, Oyebode O, Herzallah D, Nestor-Kalinoski A, Morais J Inflamm Res. 2025; 74(1):31.

PMID: 39890639 PMC: 11785624. DOI: 10.1007/s00011-025-01996-8.


Anti-Ku + myositis: an acquired inflammatory protein-aggregate myopathy.

Holzer M, Uruha A, Roos A, Hentschel A, Schanzer A, Weis J Acta Neuropathol. 2024; 148(1):6.

PMID: 39012547 PMC: 11252205. DOI: 10.1007/s00401-024-02765-3.


Cell type mapping of inflammatory muscle diseases highlights selective myofiber vulnerability in inclusion body myositis.

Wischnewski S, Thawel T, Ikenaga C, Kocharyan A, Lerma-Martin C, Zulji A Nat Aging. 2024; 4(7):969-983.

PMID: 38834884 PMC: 11257986. DOI: 10.1038/s43587-024-00645-9.


Pathologic Features of Anti-Ku Myositis.

Oyama M, Holzer M, Ohnuki Y, Saito Y, Nishimori Y, Suzuki S Neurology. 2024; 102(8):e209268.

PMID: 38547417 PMC: 11175641. DOI: 10.1212/WNL.0000000000209268.


References
1.
Rose M . 188th ENMC International Workshop: Inclusion Body Myositis, 2-4 December 2011, Naarden, The Netherlands. Neuromuscul Disord. 2013; 23(12):1044-55. DOI: 10.1016/j.nmd.2013.08.007. View

2.
Allenbach Y, Benveniste O, Goebel H, Stenzel W . Integrated classification of inflammatory myopathies. Neuropathol Appl Neurobiol. 2017; 43(1):62-81. DOI: 10.1111/nan.12380. View

3.
Sturner E, Behl C . The Role of the Multifunctional BAG3 Protein in Cellular Protein Quality Control and in Disease. Front Mol Neurosci. 2017; 10:177. PMC: 5478690. DOI: 10.3389/fnmol.2017.00177. View

4.
Weihl C, Mammen A . Sporadic inclusion body myositis - a myodegenerative disease or an inflammatory myopathy. Neuropathol Appl Neurobiol. 2017; 43(1):82-91. DOI: 10.1111/nan.12384. View

5.
Kang E, Lee S, Ascherman D, Lee Y, Lee E, Lee E . Temporal relationship between cancer and myositis identifies two distinctive subgroups of cancers: impact on cancer risk and survival in patients with myositis. Rheumatology (Oxford). 2016; 55(9):1631-41. DOI: 10.1093/rheumatology/kew215. View